ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1502

Antibodies To Anti-Type -3 Muscarinic Acetylcholine Receptor Are Highly Prevalent To Rabbits Immunized With 4-Hydroxy-2-Noneal-Modified and 60-Kda Ro

Valerie Harris1, Biji T. Kurien2, R. Hal Scofield3, Timothy Gross4 and Mary Girton5, 1Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, 2College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: auto-immunity and autoantibodies, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: In Sjörgen’s Syndrome, an autoimmune disease, the lacrimal and salivary glands are the primarily affected glands. Previous studies have proposed autoantibodies that target type-3 muscarinic acetylcholine receptors (M3R) found in salivary and lacrimal glands as a clinical marker for SS. In this study, we hypothesize that rabbits and mice immunized with 4-hydroxy-2-noneal (HNE)-modified or unmodified 60-kDa Ro will have increased levels of circulating anti-M3R and anti-Ro antibodies mirroring some of the symptoms of Sjörgen’s Syndrome.

Methods: In the first experiment, two rabbits were immunized multiple times with 500μg of 10mM of HNE-modified Ro60 and two rabbits were immunized with 500μg unmodified Ro60. In the second experiment, 50 mice, ten mice from five different strains (SJL/J, DBA, BALB/c, C57BL/6, and PL/J) were immunized subsequent times with 50μg of Ro60 peptide. In the third experiment, fifty mice were in immunized with unmodified Ro60, or low (.4mM), moderate (2mM), or high (10mM)-HNE modified Ro60. ELISA analysis was used to detect the presence of antibodies specific to Ro60, HNE-modified Ro60, and the second extracellular loop (amino acids 213-228) or the third extracellular loop (amino acids 514-527) of the type-3 muscarinic acetylcholine receptor using the serial bleeds from the immunized rabbits and mice.

Results: Immunization with HNE-modified Ro60 or unmodified Ro60 abrogates tolerance to autoimmunity. Rabbits immunized with unmodified Ro60 showed in an induction of antibodies to Ro60 and the second loop (213-228) of M3R, but not 514-527. Conversely, rabbits immunized with HNE-modified Ro60 had suppressed levels of antibodies to either variant of the M3R peptide, but showed a rapid response after immunization with increased levels of anti-Ro60 and anti-HNE Ro60 antibodies. The five strains of mice immunized with HNE-modified Ro60 or unmodified Ro60 , as well as, the mice immunized with various concentrations  of HNE-modified Ro60 had negligible levels of antibodies directed toward M3R, but both experimental groups showed an induction in anti-Ro60 antibodies.

Conclusion: We previously published data showing that the rabbits and mice immunized with unmodified or HNE-modified Ro60 developed anti-Ro antibodies, as commonly seen in circulation of SS patients. Add to that, this data which shows increasing levels of anti-M3R antibodies in rabbits immunized with Ro60, but not mice. Taken together this data suggests that second extracellular loop of the type-3 muscarinic receptor is a target in the lacrimal and salivary glands during SS autoimmunity progression in rabbits.


Disclosure:

V. Harris,
None;

B. T. Kurien,
None;

R. H. Scofield,
None;

T. Gross,
None;

M. Girton,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibodies-to-anti-type-3-muscarinic-acetylcholine-receptor-are-highly-prevalent-to-rabbits-immunized-with-4-hydroxy-2-noneal-modified-and-60-kda-ro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology